ICICI Securities recommends these 2 pharma stocks to buy

Novartis AG has entered into agreements with Dr Reddy’s Laboratories (DRL) and JB Chemicals & Pharmaceuticals (JBCPL) for his or her cardiovascular mixture of Valsartan and Sacubitril in India. The patented molecule has been rising at round 38% CAGR over FY19-21 and is among the quickest rising molecules within the cardiology phase, highlighted home brokerage and analysis agency ICICI Securities. 

“Both the transactions seem fairly valued at ~3.2-3.5x MAT February 2022 gross sales, nevertheless, patent for the medicine expire throughout the subsequent 12 months which might erode the product worth considerably,” the notice said. The brokerage has retained buy score on pharma stocks Dr Reddy’s with goal worth of 5,359 and JB Chemicals with price target of 1,963.

While DRL has acquired the Cidmus model (at the moment marketed by Lupin) for a money consideration of $61 mn, Azmarda (at the moment marketed by Cipla) has been acquired by JBCPL for a money consideration of round $32.5 mn. 

JBCPL will purchase the Azmarda model (at the moment marketed by Cipla) for a money consideration of $ 32.5mn. As per IQVIA MAT February 2022 information, Azmarda recorded gross sales of round 768 mn and has entered the highest 300 manufacturers within the month of February 2022. Though, key dangers Delay in launching new merchandise, slowdown in India development, regulatory hurdles and foreign money volatility, as per ICICI Securities.

“The acquisition is valued at ~3.2x MAT Feb’22 gross sales and is anticipated to be funded via debt (primarily) and inside accruals. Azmarda is anticipated to additional strengthen JBCPL’s presence within the cardiology phase in India. The deal is anticipated to full inside two weeks, topic to customary closing formalities,” the brokerage notice added.

The views and suggestions made above are these of particular person analysts or broking corporations, and never of Mint.

Subscribe to Mint Newsletters

* Enter a legitimate e-mail

* Thank you for subscribing to our e-newsletter.

the App to get 14 days of limitless entry to Mint Premium completely free!



Please enter your comment!
Please enter your name here